A share price of NewAmsterdam Pharma Company NV [NAMS] is currently trading at $24.69, down -1.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NAMS shares have gain 34.55% over the last week, with a monthly amount glided 0.37%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Scotiabank started tracking the stock with Sector Outperform rating on March 14, 2024, and set its price target to $35. On January 18, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $30 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $37 on January 16, 2024. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $25 as its price target on October 30, 2023.
NewAmsterdam Pharma Company NV experienced fluctuations in its stock price throughout the past year between $9.61 and $27.29. Currently, Wall Street analysts expect the stock to reach $39.33 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $24.69 at the most recent close of the market. An investor can expect a potential return of 59.3% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.96%, Pretax Profit Margin comes in at -5.35%, and Net Profit Margin reading is -5.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.54 and Total Capital is -0.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.32 points at the first support level, and at 23.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.11, and for the 2nd resistance point, it is at 25.54.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NewAmsterdam Pharma Company NV [NASDAQ:NAMS] is 10.61. Further, the Quick Ratio stands at 10.61, while the Cash Ratio is 10.25.
Transactions by insiders
Recent insider trading involved ForGrowth NAP B.V., 10% Owner, that happened on Dec 10 ’24 when 0.31 million shares were sold. 10% Owner, ForGrowth NAP B.V. completed a deal on Dec 11 ’24 to sell 0.15 million shares. Meanwhile, 10% Owner ForGrowth NAP B.V. sold 33273.0 shares on Nov 18 ’24.
